0001649989 false 0001649989 2023-02-14 2023-02-14 iso4217:USD xbrli:shares...
Pre-launch commercial activities underway as Company advances toward U.S. Food and Drug Administration (FDA...
ISELIN, N.J., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
00016499892022FYfalse00016499892022-03-3100016499892023-01-1600016499892021-10-012022-09-30xbrli:sharesiso4217:USDTable of...
ISELIN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
ISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants http://www.outlooktherapeutics.com/20220930#ChangeInF...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
0001649989 false 0001649989 2022-12-29 2022-12-29 iso4217:USD xbrli:shares...
Attained U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of August 29...
0001649989 false 0001649989 2022-12-23 2022-12-23 iso4217:USD xbrli:shares...
ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a...
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No...
ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.